Metastasen bei Aderhautmelanom

Metastatic

uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. MRI abdomen T2-hyperintense signal. a & b showing multiple metastatic lesions to the liver before the initiation of immunotherapy. c showing progression of the disease after 4 cycles of nivolumab. The largest lesion was 5.5 cm in the right hepatic lobe. d showing a mixed response after 4 cycles on ipilimumab/nivolumab

Chemosaturation

with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. a: Patient case. Of note, a depicts a patient with liver dominant metastatic uveal melanoma at baseline before first chemosaturation with percutaneous hepatic perfusion (CS-PHP) treatment. The patient responded with partial remission 3 month after first CS-PHP procedure (b). Sustained hepatic tumor control was achieved for 30 months by five treatments with CS-PHP, while extrahepatic progressive disease was noted (c). After a sixth CS-PHP application and 35 months after first CS-PHP therapy, progression was diagnosed intra- and extrahepatically (d). b: Patient case. Of note, (a) T2 weighted images of a patient with liver dominant metastatic uveal melanoma at baseline before first chemosaturation with percutaneous hepatic perfusion (CS-PHP) treatment. The patient responded with partial remission 3 month after first CS-PHP procedure (b). Sustained hepatic tumor control was achieved for 13 months (c). Progression was diagnosed intrahepatically after 17 months, and patient was scheduled for a new CS-PHP (d)